HDAC10 Antibody

What is HDAC10 and what cellular compartments should I target when using HDAC10 antibodies?

HDAC10 is a 669 amino acid protein (approximately 71 kDa) belonging to the class IIb histone deacetylase family, characterized by an N-terminal active deacetylase domain (DAC) and a unique C-terminal leucine-rich domain (LRD) . Unlike some other HDACs, HDAC10 exhibits dual localization patterns:

• Primary localization is cytoplasmic in most cell types, particularly in cancer cells

• Can shuttle between cytoplasm and nucleus in response to cellular signals

• In Sézary syndrome cells, HDAC10 demonstrates predominantly cytoplasmic localization

When designing immunofluorescence experiments, researchers should consider this dual localization pattern. For example, in Jurkat cells, HDAC10 antibodies have successfully detected the protein in both nuclear and cytoplasmic compartments . Cytoplasmic HDAC10 is particularly important for interaction studies with proteins such as autophagy regulators.

What are the primary applications for HDAC10 antibodies in research?

HDAC10 antibodies support multiple experimental approaches across various research areas:

Researchers should note that HDAC10 antibody performance may vary significantly between applications, with some antibodies optimized specifically for certain techniques .

How can I validate HDAC10 antibody specificity for my experiments?

Proper validation is essential for reliable HDAC10 antibody experiments. A comprehensive validation approach includes:

• Positive controls: Use cell lines with confirmed HDAC10 expression (HeLa, Jurkat, and MCF-7 cells are well-documented)

• Negative controls:

  • Primary antibody omission

  • Use of HDAC10 knockout/knockdown cells (CRISPR/Cas9 or shRNA approaches)

  • Isotype control (rabbit monoclonal IgG for many commercial antibodies)

• Recombinant protein validation: Test against purified N-terminal GST-tagged human HDAC10 recombinant protein fragments. The aa 1-482 fragment has been successfully used for validation

• Overexpression systems: 293T cells transfected with HDAC10 expression vectors provide excellent validation systems for antibody specificity

• Multiple antibody comparison: Validate results with antibodies from different sources targeting distinct epitopes. For example, comparing antibodies targeting aa 61-116 versus those targeting the C-terminal region

How should I design experiments to study HDAC10's role in polyamine metabolism?

Recent research has established HDAC10 as a polyamine deacetylase (PDAC) with preferential activity toward N(8)-acetylspermidine . When investigating this function:

• Substrate selection: Focus on N(8)-acetylspermidine as the primary substrate, with acetylcadaverine and acetylputrescine as secondary substrates. HDAC10 shows attenuated activity toward N(1),N(8)-diacetylspermidine and minimal activity toward N(1)-acetylspermidine

• Physiological relevance: Design experiments under polyamine-limiting conditions using difluoromethylornithine (DFMO), as HDAC10's role becomes more pronounced in these contexts

• Experimental approach:

  • Combine HDAC10 immunoprecipitation (using validated antibodies) with polyamine metabolite analysis

  • Assess HDAC10's impact on tumor growth during polyamine depletion therapy

  • Monitor conversion of exogenous N8-AcSpd to spermidine and spermine in cells with and without HDAC10 activity

• Functional readouts: Measure polyamine levels, cell proliferation rescue, and autophagy markers to comprehensively assess HDAC10's function in polyamine metabolism

What methods can I use to investigate HDAC10's role in autophagy regulation?

HDAC10 has established functions in autophagy regulation, particularly relevant in neuroblastoma and cancer research contexts . Recommended methodological approaches include:

• Autophagy flux assessment:

  • Western blot analysis measuring LC3-II/LC3-I ratio following HDAC10 knockdown or inhibition

  • Combined treatment with rapamycin (autophagy inducer) and chloroquine (autophagy inhibitor) as positive controls

  • Quantification of autophagosome accumulation upon HDAC10 silencing

• Gene silencing approaches:

  • Use multiple HDAC10-specific shRNAs to ensure specificity (minimum 3 different constructs)

  • Employ GFP growth competition assays to monitor cellular effects over time (14-23 days recommended)

  • Include appropriate non-targeting controls (NT, SCR)

• Flow cytometry analysis:

  • Combine Annexin V/7-AAD staining to assess apoptosis following HDAC10 manipulation

  • Timing is critical - optimal assessment points may differ between cell lines (e.g., day 7 post-transduction for SeAx, day 12 for Hut78)

• Immunofluorescence microscopy:

  • Co-staining with autophagy markers (LC3, p62) and HDAC10

  • Subcellular localization analysis during autophagy induction

What are the optimal methods for studying HDAC10's role in cancer models?

HDAC10 exhibits complex roles in cancer progression, showing tumor-suppressive functions in cervical cancer but pro-survival effects in Sézary syndrome . Key methodological considerations include:

• Expression analysis in patient samples:

  • Compare HDAC10 expression across normal tissue, precancerous lesions, and cancer samples

  • Correlate expression with disease severity and progression

  • Use both mRNA (RT-qPCR) and protein (Western blot, IHC) analyses

• Functional assays following HDAC10 manipulation:

  • Invasion assays to assess metastatic potential

  • Cell cycle analysis

  • Apoptosis assessment using multiple methodologies:

    • Annexin V/7-AAD staining

    • BH3 profiling to identify apoptotic dependencies

    • Western blot for apoptotic markers

• Survival pathway analysis:

  • Assess BCL-2 family protein dependence

  • Test sensitivity to BCL-2 inhibitors (venetoclax, navitoclax)

  • Monitor drug resistance phenotypes

• Gene regulatory studies:

  • ChIP assays to identify HDAC10 binding to gene promoters (e.g., miR-223)

  • Expression correlation analysis between HDAC10 and target genes

How can I develop and validate selective HDAC10 inhibitors for research applications?

Developing selective HDAC10 inhibitors requires understanding of its unique structural features. Recent structural studies have revealed:

• Key selectivity determinants:

  • The P(E,A)CE motif that forms a 3₁₀ helix constraining the active site

  • Electrostatic "gatekeeper" E274 that confers selectivity for cationic substrates

• Humanized HDAC10 models:

  • Zebrafish HDAC10 with A24E and D94A substitutions provides a model system closer to human HDAC10

  • Useful for X-ray crystallography studies of inhibitor binding

• Inhibitor design strategies:

  • Incorporate hydrogen bonding capabilities with gatekeeper E274

  • Include tertiary amine groups to enhance selectivity over HDAC6

  • Consider accommodation of bulky groups via 2Å shift in P(E,A)CE motif helix

• Validation approaches:

  • Test in parallel against multiple HDAC isozymes, particularly HDAC6

  • Assess histone and tubulin acetylation to confirm specificity

  • Use autolysosome formation assays in neuroblastoma and AML cells as HDAC10-specific functional readouts

  • Control for toxicity using normal human kidney cells

How should I investigate HDAC10's role in immune responses?

Recent research has revealed HDAC10's involvement in antiviral immunity and type I interferon responses . Key methodological considerations include:

• HDAC10 degradation assessment:

  • Monitor HDAC10 protein levels following viral infection or innate immune stimulation

  • Investigate autophagy-mediated degradation through HDAC10-LC3-II interaction studies

• IRF3 regulation studies:

  • Analyze HDAC10-IRF3 interaction via co-immunoprecipitation

  • Assess IRF3 phosphorylation status in relation to HDAC10 levels

  • Monitor TBK1-mediated IRF3 activation

• Type I IFN response measurement:

  • Quantify IFN production following HDAC10 manipulation

  • Assess downstream antiviral responses

  • Compare findings in healthy controls versus autoimmune disease samples (e.g., SLE)

• Autophagy regulation analysis:

  • Investigate the mechanisms of HDAC10 degradation during immune responses

  • Assess LC3-II interaction studies

  • Monitor autophagic flux in immune cells following stimulation

What are common issues with HDAC10 antibodies and how can I address them?

Researchers frequently encounter challenges when working with HDAC10 antibodies. Key troubleshooting approaches include:

• Non-specific bands in Western blots:

  • Increase antibody dilution (1:5000-1:50000 may be necessary)

  • Use highly purified antibodies (e.g., protein A-purified)

  • Include positive controls (recombinant HDAC10 protein)

  • Verify with HDAC10-overexpression samples

• Weak signal detection:

  • Optimize sample preparation (fresh lysates often yield better results)

  • Consider using BSA-free antibody formulations

  • Enhance detection systems (HRP-conjugated secondary antibodies at 1:20000)

  • Test multiple antibodies targeting different epitopes

• Poor immunoprecipitation efficiency:

  • Use magnetic beads for gentle isolation

  • Optimize buffer conditions (test multiple salt concentrations)

  • Elute with specific peptides rather than harsh conditions

• Inconsistent immunofluorescence results:

  • Test multiple fixation protocols (methanol vs. paraformaldehyde)

  • Include cytoskeletal counterstains (e.g., alpha-tubulin)

  • Optimize permeabilization conditions

  • Use DAPI nuclear counterstain to assess localization

How can I optimize HDAC10 ChIP experiments to study its regulatory functions?

HDAC10 has been implicated in transcriptional regulation, including the regulation of miR-223 in cervical cancer . Optimizing ChIP experiments requires:

• Crosslinking optimization:

  • Test multiple formaldehyde concentrations (0.5-1%)

  • Consider dual crosslinking approaches for improved protein-DNA fixation

  • Optimize crosslinking time (10-15 minutes typically sufficient)

• Sonication parameters:

  • Determine optimal sonication conditions empirically for each cell type

  • Aim for DNA fragments of 200-500 bp

  • Verify fragmentation by agarose gel electrophoresis

• Antibody selection:

  • Choose ChIP-validated HDAC10 antibodies

  • Perform preliminary IP experiments to confirm efficiency

  • Include isotype controls and input normalization

• Confirmation approaches:

  • Validate findings with multiple primer sets targeting the same region

  • Use positive control regions (known HDAC10 binding sites)

  • Consider ChIP-seq for genome-wide binding analysis

What factors should I consider when designing HDAC10 knockdown experiments?

HDAC10 knockdown studies require careful consideration of several factors:

• Knockdown strategy selection:

  • shRNA approaches show good efficiency in multiple cell lines

  • Test multiple shRNA constructs (minimum 3 different sequences)

  • Include appropriate non-targeting controls

• Timing considerations:

  • Cell-type specific responses require different timepoints

  • SeAx cells show optimal effects at day 7 post-transduction

  • Hut78 cells require longer evaluation (day 12 post-transduction)

• Phenotypic assessment:

  • GFP competition assays effectively track growth effects over time

  • Flow cytometry analysis of apoptosis with Annexin V/7-AAD staining

  • Western blot analysis of autophagy markers (LC3-II/LC3-I ratio)

• Control experiments:

  • Include rescue experiments with HDAC10 overexpression

  • Test effects in both cancer cell lines and normal cells

  • Combine with specific HDAC10 inhibitors for mechanistic confirmation

How can I investigate HDAC10's role in cancer drug resistance?

Recent research indicates HDAC10 involvement in therapeutic resistance in several cancer types:

• BRAF inhibitor resistance in melanoma:

  • HDAC10 depletion can resensitize resistant melanoma cells to BRAF inhibitors

  • This occurs partly through SPARC upregulation

  • HDAC10 regulates SPARC transcription by affecting histone acetylation and BRD4 recruitment

• Experimental approach:

  • Combine HDAC10 knockdown/inhibition with BRAF inhibitor treatment

  • Monitor cell growth, AMPK signaling, and autophagy markers

  • Assess correlation between HDAC10 expression and treatment response

• Methodological considerations:

  • Use multiple cell lines with varying baseline resistance

  • Include dose-response curves for accurate IC50 determination

  • Perform long-term studies (14+ days) to capture stable resistance phenotypes

What techniques should I use to study HDAC10's interactions with other proteins?

HDAC10 interacts with various cellular proteins to exert its functions. Key methodological approaches include:

• Co-immunoprecipitation strategies:

  • Use validated HDAC10 antibodies for pull-down experiments

  • Include appropriate controls (IgG, lysate without antibody)

  • Elute with specific peptides or mild conditions to preserve interactions

  • Consider reciprocal IP studies with interacting partner antibodies

• Proximity ligation assays:

  • Valuable for detecting protein-protein interactions in situ

  • Allows visualization of HDAC10 interactions in specific cellular compartments

  • Requires highly specific antibodies against both HDAC10 and interacting partners

• BioID or APEX2 proximity labeling:

  • Generate HDAC10 fusion proteins with biotin ligase domains

  • Allows identification of proximal proteins without requiring stable interactions

  • Particularly useful for identifying transient interaction partners

• Specific interaction studies:

  • IRF3-HDAC10 interactions: critical for type I IFN responses

  • LC3-II-HDAC10 interactions: important for autophagy regulation

  • MSH2-HDAC10 interactions: relevant for DNA mismatch repair

How can I integrate HDAC10 research into broader epigenetic regulation studies?

HDAC10's unique position at the intersection of histone modification, polyamine metabolism, and autophagy regulation offers opportunities for integrated research approaches:

• Multi-omics integration:

  • Combine HDAC10 ChIP-seq with RNA-seq following HDAC10 manipulation

  • Integrate metabolomics (particularly polyamine profiles) with transcriptomics

  • Correlate findings with proteomics data on acetylation patterns

• Systems biology approaches:

  • Network analysis of HDAC10 interactors and regulated genes

  • Pathway enrichment analysis to identify key regulatory nodes

  • Computational modeling of HDAC10 inhibition effects on cellular systems

• Translational investigations:

  • Correlation studies between HDAC10 expression and clinical outcomes

  • Assessment of HDAC10 as a biomarker for treatment response

  • Evaluation of combined targeting strategies (e.g., HDAC10 inhibition plus autophagy modulation)